Real-World data reveals how lung cancer drug lorlatinib performs outside the lab
NCT ID NCT07567352
First seen Jun 27, 2026 · Last updated Sep 18, 2026 · Updated 2 times
Summary
This study looks at how patients with ALK-positive advanced non-small cell lung cancer respond to the drug lorlatinib when used as their first treatment in real-world settings. Researchers will analyze data from 200 patients in a U.S. database to see how long they stay on the drug, any dose changes, and their overall health status. The goal is to understand how well the medicine works outside of strict clinical trial conditions.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- lorlatinib (Lorbrena)
- What this could lead to
- If successful, this study could show how well lorlatinib works outside of clinical trials, helping doctors make better treatment decisions for ALK-positive lung cancer.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be influenced by patient differences. It does not test a new treatment or prove cause and effect.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
200 people
The number who actually took part.
- Started
-
May 2026
- Expected to finish
-
Mar 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population are patients with advanced/metastatic non-small cell lung cancer in Flatiron Health's Advanced NSCLC Panoramic dataset.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Positive for ALK rearrangement * 18 years or older at advanced/metastatic NSCLC diagnosis date * Initiated 1L lorlatinib in the metastatic/advanced setting between 3 March 2021 and latest data cutoff available Exclusion Criteria: * Missing ALK rearrangement status * Use of alectinib in the adjuvant setting * Use of lorlatinib in a clinical trial setting
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALK-positive advanced NSCLC are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer
New York, New York, 10001, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a two-drug combo outsmart resistant lung cancer?
- Can a new drug combo outsmart resistant lung cancer?
- Can a Two-Drug punch before surgery beat ALK-Positive lung cancer?
- Can a drug duo outsmart ALK-Positive lung cancer?
- New drug cocktail aims to outsmart resistant lung cancer
- Timing is everything: new study seeks best sequence for brain metastases treatment